240 related articles for article (PubMed ID: 12650799)
1. Health-state utilities and quality of life in hepatitis C patients.
Chong CA; Gulamhussein A; Heathcote EJ; Lilly L; Sherman M; Naglie G; Krahn M
Am J Gastroenterol; 2003 Mar; 98(3):630-8. PubMed ID: 12650799
[TBL] [Abstract][Full Text] [Related]
2. Estimation of utilities for chronic hepatitis C from SF-36 scores.
Thein HH; Krahn M; Kaldor JM; Dore GJ
Am J Gastroenterol; 2005 Mar; 100(3):643-51. PubMed ID: 15743364
[TBL] [Abstract][Full Text] [Related]
3. Does cirrhosis affect quality of life in hepatitis C virus-infected patients?
Hsu PC; Krajden M; Yoshida EM; Anderson FH; Tomlinson GA; Krahn MD
Liver Int; 2009 Mar; 29(3):449-58. PubMed ID: 19267865
[TBL] [Abstract][Full Text] [Related]
4. Health state utilities and quality of life in patients with hepatitis B.
Woo G; Tomlinson G; Yim C; Lilly L; Therapondos G; Wong DK; Ungar WJ; Einarson TR; Sherman M; Heathcote JE; Krahn M
Can J Gastroenterol; 2012 Jul; 26(7):445-51. PubMed ID: 22803020
[TBL] [Abstract][Full Text] [Related]
5. Health-state utilities in liver disease: a systematic review.
McLernon DJ; Dillon J; Donnan PT
Med Decis Making; 2008; 28(4):582-92. PubMed ID: 18424560
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C.
Saeed YA; Phoon A; Bielecki JM; Mitsakakis N; Bremner KE; Abrahamyan L; Pechlivanoglou P; Feld JJ; Krahn M; Wong WWL
Value Health; 2020 Jan; 23(1):127-137. PubMed ID: 31952667
[TBL] [Abstract][Full Text] [Related]
7. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.
Levy AR; Kowdley KV; Iloeje U; Tafesse E; Mukherjee J; Gish R; Bzowej N; Briggs AH
Value Health; 2008; 11(3):527-38. PubMed ID: 18179664
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV).
Stepanova M; Younossi I; Racila A; Younossi ZM
Value Health; 2018 May; 21(5):612-621. PubMed ID: 29753360
[TBL] [Abstract][Full Text] [Related]
9. Health values of patients with chronic hepatitis C infection.
Sherman KE; Sherman SN; Chenier T; Tsevat J
Arch Intern Med; 2004 Nov; 164(21):2377-82. PubMed ID: 15557419
[TBL] [Abstract][Full Text] [Related]
10. Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan.
Sugimori H; Hirao M; Igarashi A; Yatsuhashi H; Ikeda S; Masaki N; Yotsuyanagi H; Yoda T; Odajima T; Takura T; Hirao T
Sci Rep; 2022 Oct; 12(1):17139. PubMed ID: 36229479
[TBL] [Abstract][Full Text] [Related]
11. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease.
Wells CD; Murrill WB; Arguedas MR
Dig Dis Sci; 2004 Mar; 49(3):453-8. PubMed ID: 15139497
[TBL] [Abstract][Full Text] [Related]
12. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index.
Dan AA; Kallman JB; Srivastava R; Younoszai Z; Kim A; Younossi ZM
Liver Transpl; 2008 Mar; 14(3):321-6. PubMed ID: 18306356
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
15. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
16. Patient utilities in fibromyalgia and the association with other outcome measures.
Bakker C; Rutten M; van Santen-Hoeufft M; Bolwijn P; van Doorslaer E; Bennett K; van der Linden S
J Rheumatol; 1995 Aug; 22(8):1536-43. PubMed ID: 7473480
[TBL] [Abstract][Full Text] [Related]
17. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
18. Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.
Buchanan-Hughes AM; Buti M; Hanman K; Langford B; Wright M; Eddowes LA
Qual Life Res; 2019 Feb; 28(2):297-319. PubMed ID: 30225787
[TBL] [Abstract][Full Text] [Related]
19. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection.
Hsu PC; Federico CA; Krajden M; Yoshida EM; Bremner KE; Anderson FH; Weiss AA; Krahn MD
J Gastroenterol Hepatol; 2012 Jan; 27(1):149-57. PubMed ID: 21679248
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
